

## Contents

Preface XVII

Introduction XIX

List of Contributors XXV

Abbreviations XXIX

Part I General Aspects of Analogue-Based Drug Discovery 1

1 Analogues as a Means of Discovering New Drugs 3

*Camille G. Wermuth*

1.1 Designing of Analogues 3

1.1.1 Analogues Produced by Homologous Variations 3

1.1.1.1 Homology Through Monoalkylation 3

1.1.1.2 Polymethylenic Bis-Ammonium Compounds: Hexa- and Decamethonium 3

1.1.1.3 Homology in Cyclic Compounds 4

1.1.2 Analogues Produced by Vinylogy 4

1.1.2.1 Zaprinast Benzologues 5

1.1.3 Analogues Produced by Isosteric Variations 5

1.1.3.1 The Dominant Parameter is Structural 5

1.1.3.2 The Dominant Parameter is Electronic 6

1.1.3.3 The Dominant Parameter is Lipophilicity 7

1.1.4 Positional Isomers Produced as Analogues 7

1.1.5 Optical Isomers Produced as Analogues 8

1.1.5.1 Racemic Switches 8

1.1.5.2 Specific Profile for Each Enantiomer 8

1.1.6 Analogues Produced by Ring Transformations 9

1.1.7 Twin Drugs 9

1.2 The Pros and Cons of Analogue Design 10

1.2.1 The Success is Almost Warranted 10

1.2.2	The Information is Available	11
1.2.3	Financial Considerations	11
1.2.4	Emergence of New Properties	12
1.3	Analogue Design as a Means of Discovering New Drugs	12
1.3.1	New Uses for Old Drugs	12
1.3.2	The PASS Program	14
1.3.3	New Leads from Old Drugs: The SOSA Approach	14
1.3.3.1	Definition	14
1.3.3.2	Rationale	15
1.3.3.3	Availability	15
1.3.3.4	Examples	15
1.3.3.4	Discussion	18
1.4	Conclusion	20

**2 Drug Likeness and Analogue-Based Drug Discovery 25**

*John R. Proudfoot*

**3 Privileged Structures and Analogue-Based Drug Discovery 53**

*Hugo Kubinyi*

3.1	Introduction	53
3.2	Drugs from Side Effects	54
3.3	Agonists and Antagonists	55
3.4	Privileged Structures	57
3.5	Drug Action on Target Classes	58
3.5.1	GPCR Ligands	59
3.5.2	Nuclear Receptor Ligands	61
3.5.3	Integrin Ligands	61
3.5.4	Kinase Inhibitors	63
3.5.5	Phosphodiesterase Inhibitors	64
3.5.6	Neurotransmitter Uptake Inhibitors	65
3.6	Summary and Conclusions	65

**Part II Selected Examples of Analogue-Based Drug Discoveries 69**

**1 Development of Anti-Ulcer H<sub>2</sub>-Receptor Histamine Antagonists 71**

*C. Robin Ganellin*

1.1	Introduction	71
1.2	The Prototype Drug, Burimamide, Defined Histamine H <sub>2</sub> -Receptors	71
1.3	The Pioneer Drug, Cimetidine: A Breakthrough for Treating Peptic Ulcer Disease	72
1.4	Ranitidine: The First Successful Analogue of H <sub>2</sub> Antagonists	73
1.5	The Discovery of Tiotidine and Famotidine	76

1.6	Other Compounds	77
1.7	The Use of H <sub>2</sub> -Receptor Histamine Antagonists as Medicines	78
<b>2</b>	<b>Esomeprazole in the Framework of Proton-Pump Inhibitor Development</b>	<b>81</b>
	<i>Per Lindberg and Enar Carlsson</i>	
2.1	Towards Omeprazole: The First Proton-Pump Inhibitor	81
2.2	The Treatment of Acid-Related Disorders Before Losec®	81
2.3	Pioneer Research at Hässle during the 1960s and 1970s	83
2.3.1	Toxicological Challenges	86
2.3.2	Discovery of H <sup>+</sup> , K <sup>+</sup> -ATPase: The Gastric Proton Pump	87
2.3.3	Analogue Optimization	87
2.4	The Development of Omeprazole	89
2.4.1	Further Toxicological Challenges and the Halt of the Clinical Program	89
2.4.2	Resumption of Clinical Studies	90
2.4.3	Omeprazole Reaches the Market and Supersedes H <sub>2</sub> -Receptor Antagonists	90
2.5	The Unique Action of Omeprazole	91
2.5.1	Inhibition of the Final Step	91
2.5.2	Omeprazole Binds Strongly to the H <sup>+</sup> , K <sup>+</sup> -ATPase	91
2.5.3	Inhibition of Acid Secretion and H <sup>+</sup> , K <sup>+</sup> -ATPase Activity	92
2.5.4	Omeprazole Concentrates and Transforms in Acid	93
2.5.5	Disulfide Enzyme–Inhibitor Complex on the Luminal Side	93
2.5.6	Short Half-Life in Plasma and Long Half-Life for Enzyme–Inhibitor Complex	93
2.5.7	Mechanism at the Molecular Level	94
2.5.8	The “Targeted Prodrug” Omeprazole means a Highly Specific Action	96
2.6	pH-Stability Profile	97
2.7	Omeprazole Analogues Synthesized by Other Companies	98
2.8	Omeprazole: A Need for Improvement?	103
2.8.1	The Omeprazole Follow-Up Program	103
2.8.2	No Good Alternative to the Omeprazole Structural Template	103
2.8.3	Chemical Approach	104
2.8.4	Synthesis and Screening	105
2.8.5	Isomers Seemed Unattractive	106
2.8.6	Isomer Pharmacokinetics and Pharmacodynamics in Animals	106
2.8.7	The Key Experiment in Man	107
2.8.8	Production of Esomeprazole (Mg Salt)	109
2.8.9	Omeprazole Isomers: Differences in Clearance and Metabolic Pattern	109
2.9	Summary	111

- 3 The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole 115**  
*Jörg Senn-Bilfinger and Ernst Sturm*
- 3.1 Introduction 115
- 3.2 History of Gastrointestinal Research at Byk Gulden 117
- 3.2.1 The Antacids and Cytoprotectives Projects and the Set-Up of In-Vivo Ulcer Models 117
- 3.2.2 Decision to Concentrate on Anti-Secretory Treatments and the Study of Compounds with an Unknown Mechanism of Action 118
- 3.3 Identification of the First PPI Project Candidates 121
- 3.3.1 Optimizing the Benzimidazole Moiety 121
- 3.3.2 Impact of the First PPI Project Compounds 123
- 3.4 Elucidation of the Mechanism of Action of PPIs 125
- 3.4.1 A Surprising Interrelationship Between Stability and Activity 125
- 3.4.2 Isolation and Identification of the Active Principle of the PPIs 125
- 3.5 Identification of Pantoprazole as a Candidate for Development 128
- 3.5.1 Optimizing the Pyridine Moiety and the First Synthesis of Pantoprazole 128
- 3.5.2 Selection Criteria 129
- 3.5.3 The Selection of Pantoprazole and Internal Competition with SK&F95601 130
- 3.5.4 Toxicological Problems: Project Development at Risk 131
- 3.5.5 Benefits of Pantoprazole for the Patient 132
- 3.5.6 Summary 132
- 3.6 Outlook on Further Developments 133
- 4 Optimizing the Clinical Pharmacologic Properties of the HMG-CoA Reductase Inhibitors 137**  
*Sándor Kerpel-Fronius and János Fischer*
- 4.1 Introduction 137
- 4.2 Medicinal chemistry of the Statins 138
- 4.3 Clinical and Pharmacologic Properties of the Statin Analogues 142
- 4.3.1 Fibrate Coadministration 148
- 4.4 Clinical Efficacy of the Statins 149
- 5 Optimizing Antihypertensive Therapy by Angiotensin Receptor Blockers 157**  
*Csaba Farsang and János Fischer*
- 5.1 Medicinal Chemistry 157
- 5.2 Clinical Results with Angiotensin II Antagonists 160
- 5.2.1 Mechanisms of Action 160
- 5.2.1.1 Other Effects of ARBs 161
- 5.2.2 Target Organ Protection 162

- 5.2.2.1 Left Ventricular Hypertrophy 162
- 5.2.2.2 Diabetic and Nondiabetic Nephropathy 162
- 5.2.2.3 Diabetes Prevention 162
- 5.2.2.4 Coronary Heart Disease (CHD) 162
- 5.2.2.5 Congestive Heart Failure 162
- 5.2.2.6 Stroke Prevention and Other CNS Effects 163
- 5.3 Differences Among Angiotensin AT<sub>1</sub> Receptor Blockers 163
  - 5.3.1 Structural Differences 163
  - 5.3.2 AT<sub>1</sub> Receptor Antagonism 164
  - 5.3.3 Pharmacokinetics/Dosing Considerations 164
  - 5.3.4 Drug Interactions/Adverse Effects 165
  - 5.3.5 Efficacy in Hypertension 165
- 5.4 Summary 166

## **6 Optimizing Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitors 169**

*Sándor Alföldi and János Fischer*

- 6.1 Medicinal Chemistry of ACE-inhibitors 169
- 6.2 Clinical Results with ACE-Inhibitors 173
  - 6.2.1 Hemodynamic Effects 173
  - 6.2.2 Effects of ACE-Inhibitors 174
    - 6.2.2.1 Hypotension 174
    - 6.2.2.2 Dry Cough 174
    - 6.2.2.3 Hyperkalemia 174
    - 6.2.2.4 Acute Renal Failure 175
    - 6.2.2.5 Proteinuria 175
    - 6.2.2.6 Angioedema 175
    - 6.2.2.7 Teratogenic Effects 175
    - 6.2.2.8 Other Side Effects 175
  - 6.2.3 Contraindications 176
  - 6.2.4 Drug Interactions 176
- 6.3 Differences Among ACE-Inhibitors 177
- 6.4 Summary and Outlook 179

## **7 Case Study of Lacidipine in the Research of New Calcium Antagonists 181**

*Giovanni Gaviraghi*

- 7.1 Introduction 181
- 7.2 Dihydropyridine Calcium Channel-Blocking Agents 182
  - 7.2.1 Nifedipine 182
  - 7.2.2 Felodipine 183
  - 7.2.3 Isradipine 183
  - 7.2.4 Nimodipine 184
  - 7.2.5 Nisoldipine 184

7.2.6	Amlodipine	185
7.2.7	Lacidipine	185
7.2.8	Lercanidipine	185
7.2.9	Manidipine	186
7.3	Lacidipine: A Long-Lasting Calcium Channel-Blocking Drug: Case Study	187
7.3.1	The Lacidipine Project	188
7.3.2	Synthesis	190
7.3.3	The Pharmacological Profile of Lacidipine	190
7.4	Conclusion	191

## **8 Selective Beta-Adrenergic Receptor-Blocking Agents 193**

*Paul W. Erhardt and Lajos Matos*

8.1	Introduction	193
8.2	Beta-1 Selective Blockers	201
8.2.1	Atenolol	201
8.2.1.1	Discovery	201
8.2.1.2	Synthesis	203
8.2.1.3	Clinical Pharmacology	203
8.2.2	Betaxolol	206
8.2.2.1	Discovery	206
8.2.2.2	Synthesis	209
8.2.2.3	Clinical Pharmacology	210
8.2.3	Celiprolol	211
8.2.3.1	Discovery	211
8.2.3.2	Synthesis	214
8.2.3.3	Clinical Pharmacology	215
8.2.4	Nebivolol	217
8.2.4.1	Discovery	217
8.2.4.2	Synthesis	218
8.2.4.3	Clinical Pharmacology	220
8.3	Accumulated Structure–Activity Relationships	222
8.4	Summary	226

## **9 Case Study: “Esmolol Stat” 233**

*Paul W. Erhardt*

9.1	Introduction	233
9.2	Pharmacological Target	234
9.3	Chemical Target	234
9.3.1	Internal Esters	234
9.3.2	External Esters	236
9.3.3	Structure–Activity Relationships	237
9.4	Chemical Synthesis	240
9.5	Pharmacology and Clinical Profile	241

- 9.6 Summary and Some Lessons for Today 243
- 9.6.1 Compound Libraries 243
- 9.6.2 Biological Testing 244
- 9.6.3 SAR 244
  
- 10 Development of Organic Nitrates for Coronary Heart Disease 247**  
*László Dézsi*
- 10.1 Introduction 247
- 10.2 Empirical Observations Leading to the Therapeutic Use of Classic Nitrovasodilators 247
- 10.3 Isoamyl Nitrite: The Pioneer Drug 248
- 10.4 Nitroglycerin (Glyceryl Trinitrate): The Most Successful Analogue 248
- 10.5 Isosorbide Dinitrate: A Viable Analogue with Prolonged Action 249
- 10.6 Isosorbide Mononitrate: The Metabolite of Isosorbide Dinitrate 250
- 10.7 Nicorandil: The Potassium Channel Opener Analogue with a Broad Cardiovascular Spectrum 251
- 10.8 Cardiovascular Efficacy of Organic Nitrates 252
- 10.9 Mechanism of Action of Organic Nitrates 253
- 10.10 Tolerance to Organic Nitrates 255
- 10.11 Concluding Remarks 256
  
- 11 Development of Opioid Receptor Ligands 259**  
*Christopher R. McCurdy*
- 11.1 Introduction 259
- 11.2 Pharmacology Related to the Classic Opioid Receptors. 261
- 11.3 Alkaloids from the Latex of *Papaver somniferum* Initiate Research 261
- 11.4 Morphine: The Prototype Opioid Ligand 262
- 11.4.1 Initial Studies of Morphine Analogues 263
- 11.5 Structure–Activity Relationships of Morphine Derivatives 265
- 11.6 Synthetic Analogues of Thebaine Further Define Morphinan SAR 266
- 11.7 Compounds of the Morphinan Skeleton Produce New Agents 269
- 11.8 Further Reduction of the Morphinan Skeleton Produced the Benzomorphans 270
- 11.9 Another Simplified Version of Morphine Creates a New Class of Opioid Ligand 271
- 11.10 A Breakthrough in the Structural Design of Opioid Ligands 271
- 11.11 Discovery of the 4-Anilidopiperidines 273
- 11.12 Phenylpropylamines: The Most Stripped-Down Opioids Still Related to Morphine 273
- 11.13 The Use of Opioid Analgesics in Clinical Practice: Hope of the Future 274

- 12 Stigmines 277**  
*Zeev Tashma*
- 12.1 Historical Background 277
  - 12.2 Pharmacological Activities of Physostigmine 278
  - 12.3 Chemistry and Biochemistry of Physostigmine 279
  - 12.4 Interaction of Acetylcholinesterase with Carbamates 280
  - 12.5 SAR of the Eseroline Moiety, and the Development of Miotine 282
  - 12.6 The Development of Quaternary Carbamates for Myasthenia Gravis 283
  - 12.7 Carbamates as Pre-Exposure Treatment against Organophosphate Intoxication 284
  - 12.8 Carbamates as Insecticides 286
    - 12.8.1 Structural Features 287
  - 12.9 Carbamates in the Treatment of Alzheimer's Disease 287
    - 12.9.2 Close Derivatives of Physostigmine 288
    - 12.9.3 Rivastigmine 289
- 13 Structural Analogues of Clozapine 297**  
*Béla Kiss and István Bitter*
- 13.1 Introduction 297
  - 13.2 Clozapine: The Prototype "Atypical" Antipsychotic; Some Chemical Aspects 299
  - 13.3 Preclinical Aspects 300
    - 13.3.1 Multireceptor Profile: *In-Vitro*, *In-Vivo* Similarities and Differences 300
    - 13.3.2 The Availability of Data 304
    - 13.3.3 Dopamine D<sub>2</sub> versus Serotonin 5-HT<sub>2A</sub> Affinity 304
    - 13.3.4 Affinity to other Receptors 306
    - 13.3.5 Inverse Agonism 306
    - 13.3.6 Receptor Affinity of Metabolites and Clinical Action 307
  - 13.4 Clinical Aspects 307
    - 13.4.1 Terminology 307
    - 13.4.2 Indications 308
    - 13.4.3 Dosage 308
    - 13.4.4 Clinical Efficacy in Schizophrenia 308
    - 13.4.5 Clinical Efficacy in Bipolar Disorder (Especially in Mania) 309
    - 13.4.6 Adverse Events 310
  - 13.5 Summary and Conclusions 310
- 14 Quinolone Antibiotics: The Development of Moxifloxacin 315**  
*Uwe Petersen*
- 14.1 Introduction 315
  - 14.2 Aims 320
  - 14.3 The Chemical Evolution of Moxifloxacin 321

- 14.4 Synthetic Routes 338
    - 14.4.1 *S,S*-2,8-Diazabicyclo[4.3.0]nonane 338
    - 14.4.2 Preparation of BAY X 8843 36 and its Analogues 339
    - 14.4.3 Preparation of Moxifloxacin Hydrochloride 47 339
  - 14.5 The Physicochemical Properties of Moxifloxacin 342
  - 14.6 The Microbiological and Clinical Properties of Moxifloxacin 344
    - 14.6.1 *Mycobacterium tuberculosis* 347
    - 14.6.2 Skin Infections 347
    - 14.6.3 Ophthalmology 348
    - 14.6.4 Dental Medicine 348
  - 14.7 Pharmacokinetics/Pharmacodynamics of Moxifloxacin 348
  - 14.8 Development of Resistance to Moxifloxacin 350
  - 14.9 Safety and Tolerability of Moxifloxacin 352
  - 14.10 Metabolism, Excretion and Biodegradability of Moxifloxacin 353
  - 14.11 Future Prospects for Quinolones 355
  - 14.12 Summary and Conclusions 356
- 15 The Development of Bisphosphonates as Drugs 371**  
*Eli Breuer*
- 15.1 Historical Background 371
  - 15.2 Discovery of the Biological Activity of Pyrophosphate and of Bisphosphonates 372
  - 15.3 Bone-Related Activity of Bisphosphonates 372
    - 15.3.1 Overview 372
    - 15.3.2 Osteolytic Bone Diseases 373
      - 15.3.2.1 Osteoporosis 373
      - 15.3.2.2 Osteolytic Tumors 373
      - 15.3.2.3 Paget's Disease 375
    - 15.3.3 Structure–Activity Relationships 375
      - 15.3.3.1 The Molecular Skeletons of Bisphosphonates 375
      - 15.3.3.2 Phosphonic Acid Groups 375
      - 15.3.3.3 The Geminal Hydroxy Group 375
      - 15.3.3.4 Nitrogen-Containing Side Chain 375
      - 15.3.3.5 Structure–Activity Relationships of BPs: A Summary 376
    - 15.3.4 Inhibition of Bone Resorption: The Mechanisms of Action 377
    - 15.3.5 Clinical Pharmacology of Bisphosphonates 378
    - 15.3.6 Bisphosphonates in Clinical Use 379
  - 15.4 Miscellaneous Biological Aspects of Bisphosphonates 379
    - 15.4.1 Bisphosphonates as Vehicles for Delivering Drugs to Bone 379
    - 15.4.2 Bisphosphonates as Potential Drugs for other Indications 379
      - 15.4.2.1 Antiviral Drugs 381
      - 15.4.2.2 Bisphosphonate Inositol-Monophosphatase Inhibitor: A Potential Drug for Bipolar Disorders 381

- 15.4.2.3 Hypocholesterolemic Bisphosphonates (Squalene Synthase Inhibitors) 381
- 15.4.2.4 Antiparasitic Drugs 381
- 15.4.2.5 Anti-Inflammatory and Anti-Arthritic Bisphosphonates 382
- 15.4.2.6 Cardiovascular Applications of Bisphosphonates 382
- 15.5 Conclusions 382

**16 Cisplatin and its Analogues for Cancer Chemotherapy 385**

*Sándor Kerpel-Fronius*

- 16.1 Introduction 385
- 16.2 Cisplatin 385
  - 16.2.1 Discovery 385
  - 16.2.2 Structure 386
  - 16.2.3 Mechanism of Action 386
  - 16.2.4 Pharmacokinetics 387
  - 16.2.5 Clinical Efficacy 387
  - 16.2.6 Adverse Effects 388
- 16.3 Carboplatin 389
  - 16.3.1 Development 389
  - 16.3.2 Administration and Pharmacokinetics 389
  - 16.3.4 Adverse Effects 390
  - 16.3.5 Clinical Efficacy 390
- 16.4 Oxaliplatin 390
  - 16.4.1 Development 390
  - 16.4.2 Cellular Resistance to Various Pt Analogues 391
  - 16.4.3 Metabolism and Pharmacokinetics 392
  - 16.4.4 Adverse Effects 392
  - 16.4.5 Clinical Efficacy 392
- 16.5 Summary 393

**17 The History of Drospirenone 395**

*Rudolf Wiechert*

- 17.1 General Development 395
- 17.2 Syntheses 397

**18 Histamine H<sub>1</sub> Blockers: From Relative Failures to Blockbusters Within Series of Analogues 401**

*Henk Timmerman*

- 18.1 Introduction 401
- 18.2 The First Antihistamines 402
- 18.3 Diphenhydramine as a Skeleton for Antihistamines 403
  - 18.3.1 The Diaryl Group 404
  - 18.3.2 The Linker 406

- 18.3.3 The Basic Group 406
- 18.3.4 The Analogue Principle 407
- 18.3.5 The Analogue Principle in Perspective 409
- 18.4 The New Antihistamines 411
- 18.5 Antihistamines for Which the Analogue Principle Does not Seem to Work 415
- 18.6 Inverse Agonism 415
- 18.7 A Further Generation of Antihistamines? 416
- 18.8 Conclusions 417

**19 Corticosteroids: From Natural Products to Useful Analogues 419**  
*Zoltán Tuba, Sándor Mahó, and Csaba Sánta*

- 19.1 Introduction 419
- 19.2 Corticosteroid Analogues 420
  - 19.2.1 Cortisone 422
  - 19.2.2 Hydrocortisone 423
  - 19.2.3 Prednisone and Prednisolone 424
  - 19.2.4 Fludrocortisone 424
  - 19.2.5 Triamcinolone and Triamcinolone Acetonide 425
  - 19.2.6 Dexamethasone 426
  - 19.2.7 Betamethasone 427
  - 19.2.8 Beclomethasone Dipropionate 428
  - 19.2.9 Methylprednisolone 429
  - 19.2.10 Fluocinolone Acetonide, Flunisolide, Fluocortin-21-Butylate and Flumetasone 429
  - 19.2.11 Budesonide 431
  - 19.2.12 Halobetasol Propionate 432
  - 19.2.13 Mometasone Furoate 433
  - 19.2.14 Fluticasone Propionate 434
  - 19.2.15 Loteprednol Etabonate 435
  - 19.2.16 Ciclesonide 436
- 19.3 Summary 437

**Part III Table of Selected Analogue Classes 441**  
*Erika M. Alapi and János Fischer*

**Index 553**

